Should Amgen join the biopharma breakup party? Analyst says maybe

Tracy Staton Now that the Big Pharma breakup craze has moved down the drugmaker food chain to Baxter International, should Big Biotech jump on the trend? Maybe one of that group, an ...

ThromboGenics is picking between billion-dollar bids, report says

Damian Garde Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as ...

Drugmakers, FDA need a SWAT team approach on shortages, group says

Eric Palmer The FDA has reduced the number of new drug shortages considerably, and hospitals have gotten much better at responding when they occur. But the total number of drug shortages ...

Incyte’s new CEO says his pipeline is underrated–and undervalued

Damian Garde Incyte doesn't get the respect it deserves, according to CEO Hervé Hoppenot, and, after about a month on the job, the biotech's new chief is hyping his company's ...

Gilead says payers feel comfortable with the cost of Sovaldi

Eric Palmer As soon as Gilead Sciences named a price for its highly anticipated hep C drug Sovaldi, activists pounced–and payers showed some nervousness about laying out cash ...

Boehringer says it’s fighting 2,000 lawsuits over Pradaxa safety

Tracy Staton Pradaxa has become a bigger legal headache for Boehringer Ingelheim. The German drugmaker says it's facing more than 2,000 lawsuits in the U.S., filed by patients claiming ...

UPDATED: FDA panel says Aleve should keep its heart-risk warning

Eric Palmer Bayer's painkiller Aleve carries the same heart-risk warning as other nonsteroidal anti-inflammatories, or NSAIDs, like Motrin and Advil. And as far as an FDA review ...

Singapore fling: AbbVie says a plant in Asia is just what it needs

Eric Palmer Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products ...

Bristol-Myers says it’s open to dealmaking in the cancer field

Emily Mullin Bristol-Myers Squibb says it's on the lookout for new deals, but that its focus will be on snapping up experimental treatments still in development instead of commercial ...

FDA says nada to Lemtrada; will Sanofi be willing to invest in additional trials?

Eric Palmer Sanofi intends to appeal the FDA's denial of Lemtrada, its multiple sclerosis drug that was a key reason it paid $ 20.1 billion to buy Genzyme two years ago. But will ...

Breaking up with Pfizer is hard to do, Zoetis chief says, but worth it

Tracy Staton Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer? FiercePharma News

Suffering Dendreon puts itself on the block, Bloomberg says

Tracy Staton Dendreon is getting tired of soldiering on alone. As Bloomberg reports, the Seattle-based company is casting about for buyers as its prostate cancer treatment ...
Page 5 of 8« First...34567...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS